| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $83,125,847 ) (Continued on the next page) |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA274706 | SIRT1 Regulates RNA Stability to Promote Breast Cancer | 000 | 5 | NIH | 5/12/2026 | $100,008 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA278980 | Dissecting Convergent Somatic and Germline Alterations that Mediate the Origins and Evolution of Kidney Cancer | 001 | 3 | NIH | 4/16/2026 | $67,440 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA278980 | Dissecting Convergent Somatic and Germline Alterations that Mediate the Origins and Evolution of Kidney Cancer | 000 | 3 | NIH | 2/24/2026 | $606,976 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AI176904 | Probing functional HIV-1 envelope glycoprotein conformations with novel potent CD4-mimetic compounds | 000 | 4 | NIH | 6/30/2026 | $825,965 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA255245 | Targeting vulnerabilities of PPM1D-mutant gliomas | 000 | 6 | NIH | 3/23/2026 | $404,055 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA284291 | Fertility legislation and unmet needs: Exploring intervenable barriers for quality oncofertility care among adolescent and young adult cancer patients | 000 | 4 | NIH | 4/17/2026 | $107,273 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01GM152499 | Survival Data Analysis using general censoring-free incident rate | 000 | 3 | NIH | 3/26/2026 | $331,175 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA289547 | Randomized trial of REVITALIZE: A telehealth intervention to reduce fatigue interference among adults with advanced ovarian cancer on PARP inhibitors | 000 | 3 | NIH | 6/16/2026 | $677,174 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA276268 | Mechanisms of response and resistance to KRAS inhibition in pancreatic cancer | 000 | 4 | NIH | 1/26/2026 | $505,595 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA276268 | Mechanisms of response and resistance to KRAS inhibition in pancreatic cancer | 001 | 4 | NIH | 4/16/2026 | $56,177 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA274597 | Elucidating the role of RNA splicing in the metastatic seeding and outgrowth of aggressive cancers. | 000 | 5 | NIH | 6/18/2026 | $102,773 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA266194 | Selective disruption of histone deacetylase complexes using protein interaction modulators | 001 | 5 | NIH | 4/16/2026 | $68,012 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA266194 | Selective disruption of histone deacetylase complexes using protein interaction modulators | 000 | 5 | NIH | 1/8/2026 | $612,114 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA276156 | Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies | 004 | 4 | NIH | 4/17/2026 | $999 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA276156 | Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies | 003 | 4 | NIH | 4/16/2026 | $39,691 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA276156 | Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies | 002 | 4 | NIH | 1/30/2026 | $8,991 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA276156 | Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies | 001 | 4 | NIH | 1/23/2026 | $350,562 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA273043 | Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention | 000 | 5 | NIH | 7/7/2026 | $207,900 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA283395 | Mechanisms of Toxicity Induced by EWS/FLI1 Overdose in Ewing Sarcoma | 000 | 4 | NIH | 5/1/2026 | $713,593 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA303137 | Protein O' Mannosylation as a therapeutic vulnerability in KIAA1549-BRAF-driven pediatric low-grade glioma | 000 | 1 | NIH | 6/9/2026 | $721,653 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA266424 | Tissue-based biomarkers of anti-PD-1-based therapy in metastatic renal cell carcinoma | 000 | 5 | NIH | 6/16/2026 | $713,011 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | UH3NS132127 | Single Molecule Detection of L1 Insertions and Intermediates | 000 | 4 | NIH | 3/24/2026 | $698,829 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AG071966 | Defining the landscape and mechanisms of protein redox regulation during aging | 000 | 5 | NIH | 6/19/2026 | $552,894 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA293136 | Signaling pathways in tumoricidal macrophages in pancreatic cancer | 000 | 2 | NIH | 7/7/2026 | $159,304 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R35HL183474 | Elucidating the Origins and Drivers of Clonal Dynamics in Hematopoiesis | 000 | 1 | NIH | 3/10/2026 | $445,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R13AR088535 | The Fourth International Merkel Cell Carcinoma Symposium | 002 | 1 | NIH | 4/24/2026 | $5,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R13AR088535 | The Fourth International Merkel Cell Carcinoma Symposium | 001 | 1 | NIH | 3/27/2026 | $5,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R13AR088535 | The Fourth International Merkel Cell Carcinoma Symposium | 000 | 1 | NIH | 3/9/2026 | $15,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA312809 | Defining epigenetic underpinnings of neuroendocrine lineage carcinomas | 000 | 1 | NIH | 6/30/2026 | $170,394 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK142783 | Niche regulation of gastric epithelial cell differentiation | 000 | 1 | NIH | 3/19/2026 | $740,581 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA311335 | USP1 inhibitor-mediated reversal of PARP inhibitor resistance in ovarian cancer. | 000 | 1 | NIH | 6/12/2026 | $463,279 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32DK146509 | A small-molecule methyltransferase as a direct target of metformin | 001 | 1 | NIH | 2/27/2026 | $0 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32DK146509 | A small-molecule methyltransferase as a direct target of metformin | 000 | 1 | NIH | 2/27/2026 | $78,040 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA303520 | Flipping the Switch in Cell Cycle Control: Dissecting the Molecular Mechanisms Governing Wee1 Kinase transition from Cdk Inhibitor to Substrate | 000 | 1 | NIH | 6/12/2026 | $645,102 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA302918 | From biology to therapy: mechanism-informed targeting in translocation renal cell carcinoma | 000 | 1 | NIH | 6/30/2026 | $737,086 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA312664 | Structure-function and mechanistic studies of a specific glycosyltransferase complex in fusion-driven pediatric gliomas | 000 | 1 | NIH | 6/12/2026 | $134,919 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA307422 | Reprogramming tumor-associated macrophages with theranostic nanoparticles | 000 | 1 | NIH | 7/6/2026 | $454,109 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA301574 | TIRR/53BP1 complex regulates mitotic fidelity and immune-mediated radiation response | 000 | 1 | NIH | 3/24/2026 | $683,075 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA307630 | Establishing Ethical Standards for Informed Consent and Counseling for Multi-Cancer Early Detection Testing | 000 | 1 | NIH | 4/21/2026 | $134,919 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA300940 | The biology and phenotypic consequences of B-cell clonality driven by mosaic chromosomal alterations | 000 | 1 | NIH | 4/27/2026 | $235,491 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA303334 | Context-specific pathway dependencies for nuclear envelope proteins in brain cancer | 000 | 1 | NIH | 6/25/2026 | $718,275 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21AI200817 | Developmental Potential of IN-TACKs | 000 | 1 | NIH | 5/4/2026 | $267,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279391 | Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy | 001 | 3 | NIH | 4/16/2026 | $72,700 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279391 | Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy | 000 | 3 | NIH | 1/15/2026 | $654,298 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA284254 | Defining Therapeutically Targetable Regulators of Tumor-Intrinsic Immune Suppression in Glioblastoma | 001 | 4 | NIH | 4/16/2026 | $10,313 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA284254 | Defining Therapeutically Targetable Regulators of Tumor-Intrinsic Immune Suppression in Glioblastoma | 000 | 4 | NIH | 1/13/2026 | $92,813 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK142741 | Structural Basis of Thermogenic Mitochondrial Respiratory Complexes Assembly | 000 | 2 | NIH | 4/6/2026 | $813,511 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK140171 | Cellular and Biochemical Pathways of Adipose Metabolism and Thermogenesis | 000 | 2 | NIH | 4/28/2026 | $844,198 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA286537 | Mechanism and functional consequences of dietary lipids in lineage specification and tumor growth in oncohistone gliomas | 001 | 3 | NIH | 4/13/2026 | $702,458 |
|
